ASH 2020 | DLIx as a prognostic tool for LBCL patients receiving axi-cel
Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a study aiming to evaluate the significance of patient delta lymphocyte index (DLIx) in relapsed/refractory (R/R) large B-cell lymphoma (LBCL) patients treated with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel). A complete response (CR) was achieved in 54% of patients. Patients achieving a CR exhibited higher DLIx values and low DLIx was associated with significantly shorter median progression-free survival (PFS) and overall survival (OS). These findings indicate that DLIx has a prognostic value in patients with R/R LBCL treated with axi-cel. Further studies evaluating how different factors impact DLIx may lead to optimization of conditioning therapy, thus improving CAR T-cell therapy efficacy. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
